Feeding and Eating Disorders
A group of disorders characterized by physiological and/or psychological disturbances in appetite or food intake.
Subtype terms (12)
More specific conditions that are subtypes of Feeding and Eating Disorders in the MeSH hierarchy.
- Anorexia Nervosa
43 drugs (34 approved, 9 experimental)
- Avoidant Restrictive Food Intake Disorder
1 drug approved
- Binge-Eating Disorder
32 drugs (24 approved, 8 experimental)
- Bulimia Nervosa
21 drugs (18 approved, 3 experimental)
- Diabulimia
- Feeding and Eating Disorders of Childhood
2 drugs experimental
- Food Addiction
1 drug approved
- Night Eating Syndrome
2 drugs (1 approved, 1 experimental)
- Orthorexia Nervosa
- Pica
- Relative Energy Deficiency in Sport
- Rumination Syndrome
1 drug approved
Drugs by status
Phase 4 trials (19)
Phase 3 trials (6)
Phase 2 trials (15)
Phase 1 trials (6)
Organizations
Organization Involved with Phase 4 Indications (19)
- Jazz Pharmaceuticals
- Forest Laboratories
- Eli Lilly
- National Institute of Mental Health (NIMH)
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Ain Shams University
- HealthPartners Institute
- Mclean Hospital
- Medical College of Wisconsin
- Nanjing Medical University
- Universidad Autonoma de Madrid
- University of Kansas
- University of Toronto
- Yale University
- Columbia University
- University of California, San Diego
- University of Cincinnati
- Park Nicollet
- Jiangsu University
Organization Involved with Phase 3 Indications (16)
Organization Involved with Phase 2 Indications (16)
- Takeda
- Genentech
- Alkermes
- Harvard University
- Emory University
- Institut de Cancérologie de la Loire (ICLN)
- McGill University
- Multidisciplinary Association for Psychedelic Studies
- University of Chicago
- MAPS Public Benefit Corporation
- University of North Carolina at Chapel Hill
- Charles University
- Brain & Behavior Research Foundation
- Foundation of Hope, North Carolina
- Ontario Mental Health Foundation
- Institut de Cancérologie Lucien Neuwirth
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (12)